AllianceBernstein’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,047,410
| Closed | -$75.5M | – | 3279 |
|
|
2025
Q4 | $75.5M | Buy |
1,047,410
+922,970
| +742% | +$59.6M | 0.02% | 497 |
|
|
2025
Q3 | $5.42M | Sell |
124,440
-6,390
| -5% | -$258K | ﹤0.01% | 1478 |
|
|
2025
Q2 | $3.72M | Buy |
130,830
+3,060
| +2% | +$91.2K | ﹤0.01% | 1617 |
|
|
2025
Q1 | $3.77M | Hold |
127,770
| – | – | ﹤0.01% | 1564 |
|
|
2024
Q4 | $3.72M | Sell |
127,770
-42,914
| -25% | -$1.79M | ﹤0.01% | 1633 |
|
|
2024
Q3 | $7.84M | Sell |
170,684
-45,544
| -21% | -$1.98M | ﹤0.01% | 1319 |
|
|
2024
Q2 | $8.83M | Sell |
216,228
-112,298
| -34% | -$3.22M | ﹤0.01% | 1236 |
|
|
2024
Q1 | $8.38M | Sell |
328,526
-46,150
| -12% | -$723K | ﹤0.01% | 1240 |
|
|
2023
Q4 | $3.39M | Sell |
374,676
-152,939
| -29% | -$1.02M | ﹤0.01% | 1666 |
|
|
2023
Q3 | $3.37M | Buy |
527,615
+362,215
| +219% | +$3.12M | ﹤0.01% | 1598 |
|
|
2023
Q2 | $1.83M | Buy |
165,400
+119,900
| +264% | +$1.5M | ﹤0.01% | 1947 |
|
|
2023
Q1 | $698K | Sell |
45,500
-162,560
| -78% | -$3.58M | ﹤0.01% | 2399 |
|
|
2022
Q4 | $4.62M | Buy |
208,060
+88,694
| +74% | +$1.32M | ﹤0.01% | 1470 |
|
|
2022
Q3 | $1.95M | Sell |
119,366
-152,923
| -56% | -$2.93M | ﹤0.01% | 1902 |
|
|
2022
Q2 | $3.96M | Buy |
272,289
+130,280
| +92% | +$1.94M | ﹤0.01% | 1566 |
|
|
2022
Q1 | $2.62M | Sell |
142,009
-5,307
| -4% | -$90.2K | ﹤0.01% | 1935 |
|
|
2021
Q4 | $3.5M | Buy |
+147,316
| New | +$3.52M | ﹤0.01% | 1810 |
|
|
2021
Q3 | – | Sell |
-10,700
| Closed | -$264K | – | 3334 |
|
|
2021
Q2 | $264K | Buy |
+10,700
| New | +$249K | ﹤0.01% | 3060 |
|
|
2020
Q3 | – | Sell |
-10,000
| Closed | -$283K | – | 3204 |
|
|
2020
Q2 | $283K | Buy |
+10,000
| New | +$288K | ﹤0.01% | 2904 |
|
Other funds holding RNAM
AllianceBernstein's RNAM Position: Q1 2026 in Review
AllianceBernstein sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,047,410 shares — an estimated $75.5M sold.
AllianceBernstein first reported a position in RNAM in Q2 2020 and held it in 19 quarters. The position peaked at $75.5M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- AllianceBernstein reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- AllianceBernstein sold 1,047,410 Avidity Biosciences shares in Q1 2026, an estimated $75.5M.
- AllianceBernstein first reported a position in Avidity Biosciences in Q2 2020 and held it in 19 quarters.
- AllianceBernstein's Avidity Biosciences position peaked at $75.5M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.